Dermata Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Operating expenses | $7.8M | $12.5M | $8.0M | $9.7M | — |
| Cash from operations | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922,634 | $1.5M |
Shares outstanding 4.0M · Free float 5.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.